FDA chides Eli Lilly for 2nd misleading ad in 2 months, this time for diabetes blockbuster Trulicity
After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The FDA gave Lilly a slap on the wrist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results